In October 2015, Dr. Jennifer Grandis and Dr. Jonathan George collaborated with Kolltan Pharmaceuticals in a new clinical study related to head and neck cancers that will evaluate tissue responses to KTN3379; an antibody drug developed to treat adult patients with different levels of solid tumors. Particularly, those patients who were recently diagnosed and treated with KTN3379, prior to having their surgical procedures. This study is expected to provide significant data on the effects of KTN3379, reviewing biomarker activity to create additional examinations.

Previous results have shown evidence of tumor shrinkage in patients who were treated with KTN3379, along with other therapies related to the trials. This includes squamous cell carcinoma of the head and neck, non-small cell lung, and colorectal cancers. The study will be conducted the University of Pittsburgh with Dr. Seungwon Kim as the Principal Investigator, and also at the University of California, San Francisco with Dr. Jonathan George as Principal Investigator.